Zhiquan Luo
机构：Xinyang Central Hospital
发表论文 7 篇 · 总被引 117 次 · h-index 3
代表论文
- Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial (2022 · The Lancet. Gastroenterology & hepatology · 被引 88)
- Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study (2024 · European Journal of Cancer · 被引 21)
- Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study. (2023 · Journal of Clinical Oncology · 被引 4)
- Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial. (2024 · Journal of Clinical Oncology · 被引 2)
- Camrelizumab plus with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma: A single-arm, open-label phase II clinical trial. (2025 · Journal of Clinical Oncology · 被引 1)
- A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma. (2024 · Journal of Clinical Oncology · 被引 1)